secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001711279-25-000088
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech Q3 VYJUVEK revenue $97.8M; label expanded, EU/Japan launches
----------------------------------------------------------------------------

- Q3 net product revenue $97.8M (vs $83.8M YoY); net income $79.4M ($2.74 basic EPS); cash $864.2M.
- FDA expanded VYJUVEK label to include DEB patients from birth and allow at-home application.
- VYJUVEK launched in Germany (Aug), France (Oct), and Japan (Oct); >615 US reimbursement approvals.
- FDA granted platform technology designation to HSV-1 vector used in KB801 and other programs.
- CF interim data (KB407) expected Q4; KB111 IND cleared for Hailey-Hailey disease; intratumoral KB707 enrollment paused.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000088/0001711279-25-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000088/krys-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001711279-25-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer